Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3987306 | European Journal of Surgical Oncology (EJSO) | 2010 | 7 Pages |
ObjectiveTo evaluate the contribution of preoperative serum tumor markers to manage borderline ovarian tumors (BOT).Study designRetrospective multicentre study including 317 BOT. Serum tumor marker levels of CA125, CA19-9, CEA, and CA15-3 were determined by radio-immunoassay.ResultsAmong 181 women with serous BOT and 136 women with mucinous BOT, respectively 55 of 114 (48.2%) and 38 of 91 (41.8%) had at least one abnormal value. Women with preoperative tumor marker assays were more likely to have radical treatment (p = 0.0001), full staging (p = 0.004), and intra-operative histology (p < 0.0001). Women with at least one abnormal tumor marker were more likely to undergo laparotomy (p = 0.007), to have intra-operative histology (p = 0.04) and complete staging (p = 0.0008). In multivariate analysis, first-line laparoscopy was associated with abnormal tumor marker levels (OR = 9.63; 95%CI = 1.40–66.39; p = 0.02), while laparotomy was associated with large tumors, bilateral tumors, and ascitis visible on sonography.ConclusionSerum tumor marker assays modified both preoperative assessment and surgical management of BOT.